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How did the study come about? 
The earliest reports of high incidence of oesophageal 
cancer (OC) in the northern parts of Iran date back to 
the early 1970s.1,2 A population-based cancer registry 
was established in 1969 as a joint effort between 
Tehran University and the International Agency for 
Research on Cancer (IARC). This registry confirmed 
the high incidence of OC in the eastern portion of 
the Caspian Sea littoral, in the area that is now 
known as Golestan Province. The highest incidence 
rates were reported from the semi-desert plain settled 
mainly by people of Turkmen ethnicity in Gonbad 
and Kalaleh counties, with estimated incidence rates 
of 109/105 among men and 174/105 among women 
(adjusted to the 1970 World Standard Population).3 
The registry also showed low incidence of OC in the 
nearby Gilan province, 300 km to the west of 
Golestan, with incidence rates of 15/105 and 5.5/105 
among men and women, respectively. A series of 
studies were conducted in the region in the 1970s, 
but they were not conclusive in explaining the 
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very high rates. However, they pointed to several 
factors, including: (i) a diet deficient in fruits and 
vegetables;4 (ii) low socio-economic status; (iii) ther­
mal injury from consumption of very hot tea;5 and 
(iv) carcinogen exposure from lifestyle factors includ­
ing opium consumption.6–8 The high incidence of 
OC in Golestan was confirmed by a recent screening 
study.9 
Aetiological hypotheses related to diet and life style 
can be best addressed in prospective cohort studies, in 
which measurement error can be reduced and recall 
bias is minimal.10 From 2002 to 2003, a pilot study of 
1057 subjects was conducted by the Digestive Disease 
Research Center (DDRC) of Tehran University of 
Medical Sciences in collaboration with IARC and 
the US National Cancer Institute (NCI) to evaluate 
the logistics of establishing a prospective study in 
Golestan. The aims of the pilot study were to assess 
the response rate of the study population, to develop 
valid and reliable methods for assessing nutritional, 
anthropometric and life-style factors, to develop 
follow-up methods to ascertain mortality and cancer 
incidence among the enrolled subjects, and to estab­
lish efficient procedures for collecting and storing 
biological samples. Results of the pilot study con­
firmed the feasibility of conducting a prospective 
cohort study in Golestan.11,12 Subsequently, the 
Golestan Cohort Study (GCS) was launched in 
January 2004. This study is part of a series of inves­
tigations into the etiology of upper gastrointestinal 
cancers in this area, collectively named Gastric 
and Oesophageal Malignancies in Northern Iran 
(GEMINI). The study protocol and the informed con­
sent used for this study were approved by the ethical 
review committees of DDRC, IARC and NCI. In June 
2008, the accrual goal of 50 000 subjects was reached 
and enrollment was closed. 
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What does the study cover? 
The primary aims of the GCS are: 
(i)	 To identify risk factors for OC by a comprehensive 
assessment of ethnicity, occupational history, 
socio-economic status, past medical history, 
family history of cancers, gastrointestinal symp­
toms and signs, tobacco, opium and alcohol use, 
oral health, anthropometric characteristics, physi­
cal activity and tea drinking habits, including 
tea temperature. Nutritional patterns are also 
evaluated using a food frequency questionnaire 
(FFQ) specifically developed for this population 
and validated during the pilot study.12 The FFQ 
covers 116 food items, including bread and 
cereals, meat and dairy products, oils, sweets, 
legumes, vegetables, fruits and condiments, as 
well as cooking methods. 
(ii)	 To establish biospecimen banks for blood, urine, 
hair and nail samples to be used in molecular 
and genetic studies of cross-sectional or nested 
case–control design. 
(iii)	 To provide a model for population-based studies 
in a country in economic and social transition 
based on collaboration between local health 
workers, local health authorities, national 
research centres, national government and inter­
national research institutions. 
Who is in the sample? 
The study population is a sample of the Golestan 
population, aged 40–75 years. The primary goal was 
to establish a cohort of 50 000 healthy individuals, 
with equal numbers of men and women, 20% from 
urban areas and 80% of Turkmen ethnicity. We 
enrolled the urban participants from Gonbad City, 
the second largest city of Golestan, with 126 797 inha­
bitants (28 102 aged 40–75), and the rural participants 
from villages in Gonbad, Kalaleh and Aq-Qala coun­
ties (Figure 1), with 347 683 inhabitants (53 121 aged 
40–75). 
A total of 16 599 urban inhabitants older than 
40 years were selected randomly from five areas 
of Gonbad City by systematic clustering based on 
household number. The selected inhabitants were 
contacted at home by specially trained health workers 
and invited to visit the Golestan Cohort Study Center, 
a research centre specifically established for this pro­
ject in Gonbad, to participate in the study. A total of 
10 032 urban participants were enrolled from Gonbad, 
with participation rates of �70% for women and 50% 
for men. 
In rural areas, recruitment took advantage of the 
network of health houses, primary health care centres 
present in each group of villages, which are typically 
staffed by two auxiliary health personnel (locally 
called the Behvarz). The Behvarz are in charge of vac­
cination programs, family planning, reporting births, 
deaths and major communicable diseases, and initial 
primary care treatment. All residents of all villages in 
the study catchment area who were eligible for this 
study were invited to participate. Temporary recruit­
ment centres were established in the health houses of 
198 selected villages, and the Behvarz accompanied 
the GCS research team to contact the selected subjects 
at their homes. The invitation group thoroughly 
explained the purpose and procedures of the study 
to the eligible subjects and invited them to participate 
Figure 1 Geographic location of Golestan province in northern Iran. The dashed area approximately corresponds to the 
GCS field 
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Table 1 Demographic characteristics of the 50 045 participants and 18 308 non-participants in the GCS (2004–08)
 
Place of residencea Ethnicitya 
Total Urban Rural Turkmen Non-Turkmen 
Participants 
All 50 045 20.0 80.0 74.4 25.6 
Men (years) 21 241 18.5 81.5 75.6 24.4 
445 5394 19.4 80.6 76.4 23.6 
46–55 7973 17.0 83.0 77.0 23.0 
56þ 
Women (years) 
7874 
28 804 
19.4 
21.2 
80.6 
78.8 
73.6 
73.6 
26.4 
26.4 
445 8877 19.7 80.3 74.3 25.7 
46–55 11 532 20.8 79.2 74.0 26.0 
56þ 
Non-participants 
8395 23.3 76.7 72.3 27.7 
All 18 308 35.9 64.1 – – 
Men 11 361 34.7 65.3 – – 
Women 6947 37.8 62.2 – – 
aThese data are row percentages. 
in the study. If an eligible subject did not fully under­
stand the procedures, he/she was invited to visit the 
study centre and observe all steps of the study in 
person. A total of 40 013 participants were enrolled 
from 326 villages, with participation rates of 84% for 
women and 70% for men. 
Exclusion criteria were: (i) unwillingness to 
participate at any stage of the study for any reason; 
(ii) being a temporary resident; and (iii) having 
a current or previous diagnosis of an upper gastro­
intestinal (UGI) cancer. The only data recorded 
about non-participants were their gender and place 
of residence (urban or rural). Before interview, a 
written informed consent was obtained from each 
participant. 
Each subject was interviewed by a trained general 
physician and a trained nutritionist, either in the local 
language (Turkmen) or in the national formal 
language (Persian), depending on the participant’s 
preference. Two structured questionnaires were 
administered: a life-style questionnaire and an FFQ. 
Following the questionnaires and a limited physical 
examination, samples of blood (10 ml), urine 
(4.5 ml), hair (3 cm from the base of scalp) and 
nails (trimmings from all 10 toenails) were collected 
by a trained technician. In the urban area, all 
biological samples were immediately processed in 
the central laboratory at the Golestan Cohort Study 
Center. In the rural areas, blood and urine samples 
were kept in refrigerators (þ48C), until they were 
transferred in cooling boxes to the central laboratory; 
the maximum duration between blood collection 
and final processing was 8 h. The blood samples 
were centrifuged and aliquoted in 500 ml straws 
(eight straws of plasma, four straws of buffy coat 
and two straws of red blood cells) and stored at 
-808C. Urine samples were stored at -208C, and 
hair and nail samples were stored at room tempera­
ture. Half of the frozen blood samples were subse­
quently transferred on dry ice to DDRC in Tehran, 
and then shipped at regular intervals to IARC in 
Lyon, France, where they are stored in nitrogen 
vapour (approximately -1358C). 
All participants received a personal GCS identifica­
tion card at the time of enrollment, which allows 
them to come to Atrak Clinic if they experience any 
gastrointestinal symptoms. Atrak Clinic is a specia­
lized gastrointestinal clinic established by DDRC in 
the main hospital in Gonbad,13 and provides free 
services for the GCS participants. 
Table 1 shows demographic characteristics of the 
cohort participants and non-participants. Compared 
with participants, the non-participants were more 
likely to be men and to live in urban areas. The dis­
tribution of participants by place of residence and 
ethnicity is close to the initial goal; however, because 
of a higher response rate, the number of women in 
the cohort (n ¼ 28 804) is higher than that of men 
(n ¼ 21 241). 
How are the subjects being 
followed up? 
Follow-up procedures 
All participants are being followed up actively every 
12 months. Each cohort member was also instructed 
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at the time of enrollment to contact the GCS team in 
case of certain conditions like hospitalization or devel­
opment of a new major disease. These contacts are 
registered and subsequently followed up. The data­
bases of Atrak Clinic and of the Golestan Cancer 
Registry are also reviewed monthly to look for 
cancer cases among the study subjects. The follow-up 
is expected to continue for a minimum of 10 years. 
Ninety-eight percent of participants have a private 
telephone line. At the time of baseline registration, 
the participants were questioned about their home 
and mobile phone numbers. They were also asked to 
provide two other phone numbers of family members, 
neighbours or close friends. The participants are first 
contacted by telephone, if they have a number. If a 
study participant is not accessible after seven attempts 
(on different days during 2 consecutive weeks), the 
GCS team calls other phone numbers available for 
that participant. If this approach is still unsuccessful, 
in urban areas the GCS team visits the participant at 
their home, and in the rural areas, the team contacts 
the Behvarz and asks them to complete a case review 
questionnaire. 
The GCS team completes a case review question­
naire during each phone call or home visit and 
records the vital status of the participant and any 
occurrence of disease or hospital admissions that 
have taken place since the previous follow-up contact. 
The participants are also questioned about any plans 
to change their place of residence in near future. 
In case a death, cancer or UGI endoscopy is reported, 
the GCS team visits the participant’s home and the 
medical centres in which any major diagnostic or 
therapeutic procedures were done. The team collects 
all clinical reports, pathology reports and hospital 
records, and any tumor samples that are available. 
14,15For deceased participants, a verbal autopsy is 
also performed. 
Up to August 2008, the GCS team contacted 41 008 
[10 780 (26.3%) urban and 30 228 (73.7%) rural] par­
ticipants through 74 922 phone calls or home visits. A 
total of 19 556 participants were followed once, 12 160 
participants twice, 6122 participants three times and 
3170 participants four times. The success rate of the 
follow-up during the first 4 years has been 99.8%. 
Case confirmation and outcomes 
Three types of outcomes are assessed in the GCS: 
death (from any cause), occurrence of any cancer 
(of any site) and occurrence of a UGI cancer (oeso­
phageal or gastric cancer). Two external internists 
independently review all available clinical documents 
and allocate a disease code and a date of occurrence 
to each outcome. The two disease codes are compared, 
and if they are different, a third, more senior internist 
reviews the data and makes the final decision on the 
code. UGI cancer are the most important outcomes of 
the study, so they are further reviewed and verified by 
an International Endpoint Review Committee (IERC) 
composed of experts from DDRC, IARC and NCI. 
What has the GCS found? 
The GCS is currently too young to provide prospective 
results regarding the aetiology of OC in Golestan. 
Nevertheless, we have analysed and present data on 
baseline demographic characteristics and habits of the 
study population, cancer incidence and cause-specific 
mortality, distribution of some cancer risk factors and 
evidence for internal validity and repeatability of the 
collected data. 
Baseline demographic characteristics 
and habits 
Table 2 shows some of the baseline characteristics of 
the GCS population. About 50% of men and 85% of 
women had no formal education. The highest attained 
educational level was lower in older subjects and 
among women, compared with younger subjects and 
men, respectively. The GCS confirms previous findings 
of a low prevalence of tobacco smoking, nass (a kind 
of smokeless tobacco) chewing and alcohol drinking 
in this population, particularly among women.4,11 
Among men, 60% had never smoked tobacco, and 
83 and 92% had never used nass or alcohol, respec­
tively. Among women, the rates of tobacco smoking 
and consumption of nass and alcohol were negligible. 
Twenty-two percent of men and 7% of women were 
current opium users. 
Cancer incidence and cause-specific mortality 
Until August 2008, the total number of cancers iden­
tified in the cohort was 243 (Table 3), which corre­
sponds to a crude incidence rate of 324 per 100 000 
person-years. OC was the most common cancer, com­
prising nearly 25% of all cancer cases. All OC cases 
had endoscopy reports and were histologically con­
firmed. Of the 60 OC cases, 37 were diagnosed 
in Atrak Clinic. The age-standardized incidence rate 
of OC (per 100 000 person-years) was 82.6 among 
men and 95.7 among women. Other major cancers 
were stomach, breast, leukaemia, lung, colorectal 
and pancreatic cancer. The total number of deaths 
was 743, for a crude total mortality rate of 992 per 
100 000 person-years (Table 4). Cardiac diseases were 
the most common cause of death, followed by cancer 
and stroke, in both urban and rural areas. A total of 
2397 GCS participants were referred to Atrak clinic by 
August 2008; 202 underwent endoscopy, and OC was 
diagnosed in 37. 
Distribution of some cancer risk factors 
Several sub-studies were conducted within the pilot 
study of the GCS. Exposure to polycyclic aro­
matic hydrocarbons (PAHs), estimated by measuring 
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Table 2 Education and habits of the 50 045 participants in the GCS (2004–08), by age and sexa 
Men, by age (years) Women, by age (years) 
Highest educational level 
445 46–55 56þ 445 46–55 56þ Total 
University/college 6.8 5.4 1.7 0.9 0.4 0.1 2.1 
9–12 years at school 23.8 11.7 4.2 4.3 1.8 0.3 6.3 
6–8 years 13.1 8.8 4.8 2.7 1.4 0.6 4.5 
1–5 years 31.3 30.7 17.9 19.2 8.3 3.0 16.9 
No schooling 25.0 43.4 71.4 72.9 88.1 96.0 70.2 
Tobacco smoking 
Current smoker 27.8 20.0 16.1 1.4 1.9 2.4 10.5 
Ex-smoker 12.1 16.5 21.2 0.4 0.7 1.6 7.7 
Never smoker 60.1 59.5 62.7 98.2 97.4 96.0 81.8 
Nass chewing 
Current 9.4 12.0 17.6 0.4 0.8 1.8 6.2 
Ex-chewer 1.1 2.6 5.1 0.0 0.1 0.2 1.4 
Never chewer 89.5 85.4 77.3 99.6 99.1 98.0 92.4 
Alcohol drinking 
Current 2.9 1.8 0.7 0.0 0.0 0.0 0.7 
Ex-drinker 5.0 6.6 7.0 0.0 0.0 0.0 2.7 
Never drinker 92.1 91.6 92.3 100.0 100.0 100.0 96.6 
Opium consumption 
Current 22.9 23.0 22.2 4.7 7.2 9.3 13.7 
Ex-user 3.8 6.4 7.6 0.6 0.8 2.1 3.3 
Never user 73.3 70.6 70.2 94.7 92.0 88.6 83.0 
aAll data are column percentages. 
Table 3 The most common cancers diagnosed 
among the participants of the GCS during 
the first 4 years of follow up (2004–08) 
Cancer Number (%) 
Oesophagus 60 (24.7) 
Stomach 29 (11.9) 
Breast 15 (6.2) 
Leukaemia 13 (5.4) 
Lung 12 (4.9) 
Colorectal 10 (4.1) 
Pancreas 10 (4.1) 
Lymphoma 8 (3.3) 
Ovary 7 (2.9) 
Other 79 (32.5) 
Total 243 (100) 
a stable urinary metabolite, was high in the great ma­
jority of the participants, most of whom were non­
smokers.16 Median serum selenium was 155 mg/l, 
which suggests that the population of Golestan 
Table 4 The most common causes of mortality 
in the Golestan Cohort Study during the first 
4 years of follow up (2004–08) 
Cause of Death Number (%) 
Cardiac disease 235 (31.6) 
Cancer 164 (22.1) 
Stroke 120 (16.2) 
Vehicle accident 33 (4.4) 
Other 153 (20.6) 
Pending 15 (2.0) 
Unknown 23 (3.1) 
Total 743 (100) 
receives adequate selenium and selenium deficiency 
is not a risk factor for OC in this region.17 Contam­
ination with carcinogenic mycotoxins was not found 
in a limited number of raw rice, sorghum and wheat 
samples that were collected from the region.11 Symp­
toms of gastro-oesophageal reflux disease were 
common among pilot study participants, and 31% 
experienced these symptoms at least once a week.18 
Approximately 4.3% of the pilot study participants 
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Table 5 Distribution of selected variables in 698 participants of the GCS who were interviewed twice, 
4 years aparta 
Percentb 
Characteristic First interview Second interview Kappa statistics 
Ethnicity 1.00 
Turkmen 97.4 97.4 
Non-Turkmen 2.6 2.6 
Highest educational level 0.87c 
University/college 1.3 1.6 
9–12 years at school 3.9 2.7 
6–8 years 3.0 2.3 
1–5 years 12.9 12.2 
No schooling 78.9 81.2 
Tobacco smoking 0.85 
Ever smoker 11.3 11.9 
Never smoker 88.7 88.1 
Nass chewing 0.78 
Ever chewer 4.7 5.0 
Never chewer 95.3 95.0 
Opium consumption 0.76 
Ever user 11.8 14.6 
Never user 88.2 85.4 
aThe mean interval between the two interviews was 45 months.
 
bAll data are column percentages.
 
cWeighted kappa statistic.
 
were positive for hepatitis-B surface antigen 
(HBsAg),19 and we have developed a plan to enroll 
them in a separate cohort of HBV carriers. In data 
obtained from twelve 24-h dietary recalls, rural resi­
dents reported significantly lower intake of several 
food groups and nutrients, and intake of some 
vitamins was lower than the recommended values 
among rural dwellers and women. 20 The prevalence 
of the gluten-sensitive enteropathy was 1%, so this 
disease is unlikely to have a major impact on the 
incidence of OC in Golestan.21 Average body mass 
index (BMI) in a subset of GCS participants was 
shown to be high; the prevalences of overweight 
(BMI 525) and obesity (BMI 530) were 63.5 and 
28.4%, respectively.22 
Internal validity and repeatability 
The pilot study interviewed 1057 study subjects, 
and a repeat interview was performed on 131 sub­
jects 2 months after the first interview. The kappa 
statistics for agreement were above 0.7 for most 
variables, including tobacco, nass, opium and alcohol 
consumption, as well as for most self-reported gastro­
oesophageal symptoms.11 Two different methods 
were examined for estimating the temperature at 
which tea was usually consumed, and the method 
with the higher repeatability (kappa statistics ¼ 0.71) 
was selected for use in the actual cohort.11 The valid­
ity of the questionnaire data about opium use was 
assessed in 150 subjects by comparing their question­
naire responses with the presence of codeine or 
morphine in their urine; the questionnaire responses 
had a sensitivity of 0.93 and a specificity of 0.89 for 
identifying subjects with these urinary opium meta­
bolites.23 There was also a good agreement between 
self-reported current tobacco smoking or nass use and 
positive urinary cotinine.11,23 To validate the study 
FFQ, twelve 24-h recall questionnaires (one every 
month) and four FFQs (one in each season) were 
administered to 131 participants during 1 year. 
There was good correlation between FFQ and recall 
data on food group and nutrient intakes, and there 
was acceptable correlation between FFQ data and bio­
marker measurements.12 
To examine the repeatability of the data collected in 
the actual cohort, we repeated the entire enrollment 
process, including interviews and sample collections, 
in 698 cohort participants from rural areas. The mean 
interval between the first and second enrollments was 
45 months. Representative results are presented in 
Table 5; they show very good agreement between 
data collected at the two interviews. 
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What are the main strengths 
and weaknesses? 
Strengths and advantages 
(i)	 Establishing the first large, population-based 
prospective study in Western or Central Asia 
which has detailed exposure assessments, bio­
logical samples and virtually complete follow-up. 
(ii)	 Building capacity in terms of training researchers 
locally and at DDRC, and creating a research 
infrastructure, including Atrak Clinic. 
(iii)	 Conducting high-quality follow up with 
negligible loss to follow up and detailed infor­
mation on cancer occurrence and causes of 
death. 
(iv) Applying	 international standards for long-term 
bio-banking of biological samples. 
(v) Repeating	 measurements (interviews and bio­
sampling) in 698 GCS participants and docu­
menting the reproducibility of the results. 
(vi) Explaining the study methods to people with no 
formal education by asking them to visit the study 
centre and observing the procedures before obtain­
ing informed consent;24 a method which could 
be used in other areas with low literacy. 
In addition, the GCS is a main core and logistical sup­
porter for multiple ongoing studies of gastrointestinal, 
hepatic, metabolic, nephrologic and cardiac diseases, 
including studies of PAH exposure, a prospective study 
of viral hepatitis, and a clinical trial of the effect of a 
poly-pill in preventing cardiovascular events. 
Weaknesses 
(i)	 Lack of a systematic update of exposure infor­
mation is one weakness of the study. However, 
since the majority of the oesophageal cancer 
cases will be diagnosed or treated at Atrak 
Clinic, exposure information can be updated at 
those visits for these subjects. If further funds 
become available, updating the exposure data 
on all or a subset of the study participants will 
be feasible. This could help in analysing socio­
economic, food pattern and life-style changes 
among the participants over several years, and 
could reduce exposure misclassification. 
(ii)	 International funds may be needed for long-term 
follow up and conduct of nested case–control 
analyses. 
Can I get hold of the data? 
Where can I find out more? 
Information about the study design, updated interim 
analyses, ongoing sub-studies and relevant publica­
tions are available at www.ddrc.ac.ir. Specific propo­
sals for national and international collaborations are 
welcomed. Initial proposals, which include the aim of 
the proposed study, the required data and a time­
table, should be submitted to R.M. (malek@ams.ac.ir) 
or P.B. (boffetta@iarc.fr). The proposals will be 
discussed within the steering committee, which 
includes the principal investigators of the study and, 
if necessary, other experts according to the proposal’s 
theme. 
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